Introduction {#sec1-1}
============

Vitamin A (VA) is an essential nutrient needed in small amounts for the normal functioning of the visual system, growth and development, maintenance of epithelial cellular integrity, immune function and reproduction. Severe deficiency of VA is known to produce corneal xerophthalmia, keratomalacia and blindness in children. Vitamin A deficiency (VAD) is mainly seen amongst the young children as they have high requirements due to increased physical growth and have low dietary intake. Further, episodes of illnesses such as acute respiratory tract infection and measles, which deplete VA reserves from the body, are common in this age group[@ref1].

This article focuses on the urgent need for adopting a targeted instead of universal approach for the massive dose vitamin A (MDVA) prophylaxis programme. This approach is justified on the basis of available scientific evidence documenting: *(i)* a decline in the prevalence VAD in the country, *(ii)* side effects of MDVA supplementation, and *(iii)* resource constraints with competing priorities.

Evolution of VA supplementation (VAS) programme in India {#sec2-1}
--------------------------------------------------------

The National Prophylaxis Programme against Nutritional Blindness due to Vitamin A Deficiency (NPPNB due to VAD) was initiated in 1970 with the specific aim of preventing nutritional blindness due to keratomalacia[@ref2]. The Programme was started as a 100 per cent centrally sponsored programme. It was launched as an urgent remedial measure to combat the unacceptably high magnitude of xerophthalmic blindness in the country reported in the 1950s and 1960s. To begin with, this Programme was initiated in 11 States of the country. Evaluation studies conducted by the National Institute of Nutrition (NIN), Hyderabad in 1976 in two States revealed positive results of the Programme. In subsequent years, the Programme was extended to all States in the country[@ref3].

In 1994, under the National Child Survival and Safe Motherhood (CSSM) Programme, the NPPNB due to VAD was modified keeping in view of the vulnerability of VA deficiency in young children[@ref4]. The age group of eligible children for coverage was restricted to 9 to 36 months of age. Accordingly, each child was to receive five doses of VA before her/his 3^rd^ birthday (children age 6-11 months, 1 dose of 100,000 IU of VA and in age 12- 36 months of age one dose of 200,000 IU of VA every six months). In view of operational feasibility, the administration of first dose of VA was linked to measles immunization.

In 2006, the age group of eligible children was revised as 6-59 months. This was done after reconsidering the recommendations of WHO, UNICEF and Ministry of Women and Child Development[@ref5]. This was despite the evidence that clinical VAD was limited to a few isolated geographical pockets in the country. A National survey conducted by Indian Council of Medical Research (ICMR) in 2001, covering 16 districts in all five regions of the country showed that only three out of 16 districts had prevalence of Bitot spots (BS) of 0.5 per cent and more ([Table](#T1){ref-type="table"})[@ref6].
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Presently, vitamin A supplementation (VAS) is implemented through the existing network of primary health centres and sub-centres. The female multipurpose worker and other paramedics at the village level sub-health centres are responsible for administering vitamin A solution. The services of Integrated Child Development Services (ICDS) functionaries are also utilized for the implementation of the Programme. Monthly intensive drives are undertaken every six months to achieve universal coverage of those children who could not be covered during the routine visits of health functionaries.

Current status of VAD {#sec2-2}
---------------------

Clinical VAD has declined drastically during the last 40 years. There has been virtual disappearance of keratomalacia, and a sharp decline in the prevalence of Bitot spots[@ref7]. The decline antedated an efficiently functioning VAS programme; an increase in coverage with universal vitamin A supplementation in recent years was not associated with disappearance or substantial decline of clinical deficiency. Recent surveys indicate that the prevalence of Bitot spots of 0.5 per cent and more (conventional cut-off to define public health problem) is limited to population groups which are socio-economically backward, poverty stricken and have poor health infrastructure. Also, clinical VAD is seen only in certain seasons when green leafy vegetables are in short supply[@ref8]. Repeat surveys of the National Nutrition Monitoring Bureau (NNMB), ICMR conducted in the same villages have shown that prevalence of Bitot\'s spots had declined from 1.8 to 0.7 per cent in 1996-1997 as compared with 1975-1979[@ref9]. The prevalence of Bitot\'s spot amongst children in 6-71 months of age has been most commonly utilized as an indicator of VAD in a population. However, with disappearance of Bitot\'s spot, now the subclinical deficiency of VA, as assessed by serum retinol (SR) levels is being advocated and utilized as a marker of VAD[@ref10]. Serum retinol may not be an operationally feasible indicator to be utilized in communities to establish the prevalence of VAD. Estimation of SR requires collection of blood samples of children and sophisticated laboratory equipment[@ref11].

### Validity of SR in predicting VAD {#sec3-1}

The acceptability, technical feasibility and performance of SR in predicting VAD in communities has been debated. There are many factors that can influence SR levels and hence its validity as an indicator of VAD has been questioned[@ref12]. After administration of massive dose of VA, the serum retinol remains elevated only up to 60 days and then comes back to deficiency level for serum cut-off\'s for VAD. Retinol transport in the blood requires two specific proteins, retinol binding protein (RBP) and transthyretin (TTR). Synthesis of RBP is dependent on child\'s protein, retinol, iron and zinc status. Zinc status influences several aspects of vitamin A metabolism including its absorption, transport and utilization. Zinc deficiency impairs synthesis of RBP which affects retinol transport from liver to the blood and other tissues[@ref13][@ref14]. Iron deficiency affects vitamin A metabolism leading to reduction in serum retinol and an increase in hepatic retinol and retinyl esters[@ref15]. The mobilization of vitamin A from the liver is hampered in protein calorie malnutrition, dietary protein is required to mobilize liver reserves of vitamin A into the blood stream and increased protein intake results in greater vitamin A requirement[@ref16]. Plasma retinol is reduced by clinical and subclinical infection[@ref17][@ref18].

Overestimation of VAD burden with serum retinol {#sec2-3}
-----------------------------------------------

There have been several reports mentioning higher prevalence of VAD in different parts of the country based on serum retinol levels. A recent report documented 61 per cent prevalence of VAD in children in rural areas of West Bengal using estimation of SR. However, simultaneously serum C reactive protein (CRP) levels were not conducted to adjust for concomitant subclinical infection[@ref10]. Similar studies have been reported from other parts of the country which do not provide true status of the burden of VAD in the country. These studies are based on estimation of SR levels which have not been adjusted for CRP levels[@ref11][@ref12]. Also additional factors influencing serum retinol levels were not considered. Vitamin A deficiency burden in India is, therefore, likely to be overestimated on the basis of serum retinol measurements alone.

Reasons for decline in VAD in India {#sec2-4}
-----------------------------------

During the last four decades indicators of child health have shown substantial gains in different States in the country. The prevalence of severe undernutrition has come down significantly. Immunization coverage for measles and other vaccine preventable diseases has improved from 5-7 per cent in early seventies to currently 60-90 per cent, in different States. Similarly, there has been a significant improvement in the overall dietary intake of young children[@ref19]. The Government is also addressing the issue of food insecurity. The ICDS which covers 80 per cent of rural India provides nutritional supplements to children less than six years of age, nutrition education to mothers and also facilitates the distribution of vitamin A supplements. Improvements in infrastructure have led to better access to health care facilities. Food availability in India has improved in the last 30 years. All these factors have positively influenced the VA status of children and led to reduced prevalence of VAD in the country[@ref20].

VAS and under five mortality reduction in India {#sec2-5}
-----------------------------------------------

Child deaths can be substantially decreased in any community with the implementation of primary health care activities. Infants and children in economically poor communities die of common diseases whose detection, cure and even prevention can be done with non-expensive appropriate technology applied by a primary health care worker. The major causes of child mortality in India are diarrhoea, respiratory infections and low birth weight (prematurity)[@ref21]. These causes contribute to more than 80 per cent of the child mortality beyond the first month of life. Evidence suggests that vitamin A supplementation does not have any impact on reduction of morbidity and mortality due to diarrhoea, respiratory infections and low birth weight[@ref22].

All the populations have different epidemiological characteristics. What is true in Indonesia may not be true for Nigeria and similarly for India. This is also reflected in varying results of randomized control trials for evaluating the impact of VA supplementation on under five mortality, conducted in different countries. Investigations carried out by National Institute of Nutrition (ICMR), Hyderabad did not substantiate the mortality reduction claim of VAS found in other countries of the world[@ref23]. A meta-analysis of VAS concluded that the findings of these trials are not consistent and there is no scientific evidence as yet in favour or against substantive benefit of universal vitamin A supplementation to children in India[@ref24]. Subsequently, one of the largest trials exploring the role of massive-dose vitamin A administration in reducing childhood mortality was conducted in 72 blocks in Uttar Pradesh between 1999 and 2004. Children from different areas were given six-monthly massive doses of vitamin A, six-monthly de-worming or both or neither. Approximately one million children were followed and mortality rates in children 1-6 yr of age were recorded. There was no significant difference in death rates between children who received the massive-dose of vitamin A and those who did not[@ref25]. Thus the collated evidence from India does not support the under five mortality reduction claim of massive dose vitamin A prophylaxis.

Problems with current MDVA policy {#sec2-6}
---------------------------------

Under the present, national government policy a total of nine massive doses of synthetic vitamin A are to be given to all children between the ages of 9 and 60 months irrespective of their socio-economic and nutritional status. In India in 1999-2000, vitamin A administration was briefly linked to pulse polio immunization to universalize coverage rapidly. This approach was discontinued after the Assam tragedy and a strong opposition by the Indian Academy of Pediatrics[@ref26].

### Unjustified claims of benefit {#sec3-2}

Administration of massive doses of vitamin A is advocated on the grounds that this could bring about a 23 per cent reduction in mortality. However, benefits on this scale have been found only in areas with rudimentary health care facilities where clinical deficiency is common, and the biological mechanisms suggested as explanations are conjectural. Two recent Cochrane systematic reviews assessing the effects and safety of vitamin A supplementation in children 6-59 months of age have been published[@ref27][@ref28]. One review evaluated the effectiveness of vitamin A supplements in the prevention of morbidity and mortality in children 6-59 months of age. It showed that giving vitamin A supplements to children reduces the rates of mortality and some diseases[@ref27]. A meta-analysis of 17 trials (11 in Asia, 5 in Africa and 1 in Latin America) for all-cause mortality indicated that vitamin A reduces the overall risk of death by 24 per cent \[risk ratio (RR) 0.76; 95% confidence interval (CI) 0.69-0.83\]. When an unpublished cluster-randomized trial involving one million children in north India (the DEVTA trial) was considered, vitamin A supplementation reduced the effect size of all-cause mortality from 24 to 12 per cent (RR 0.88; 95% CI 0.84-0.94)[@ref26]. Further, when only Indian trials were considered, there was no evidence of a mortality benefit[@ref24].

### Indiscriminate mega-dosing {#sec3-3}

Universal supplementation of vitamin A to Indian children is being undertaken irrespective of their family background and nutritional status. However, deficiency is now limited to isolated geographical pockets in the country. Also, there is no evidence of benefit of VA supplementation of children without clinical signs of deficiency. Vitamin A is toxic in high doses. The mega-dose of vitamin A (200, 000 IU) given to children is 500 times higher than the daily recommended dose (400 IU). Children hospitalized for acute infectious diseases with low vitamin A status on admission tend to benefit from high-dose supplements, but no benefits and even adverse effects are observed among those with adequate pre\--admission vitamin A status[@ref29]. It is, therefore, inappropriate to administer a pharmacological dose of vitamin A to a child whose vitamin A status is adequate. At present, the National Programme for Prophylaxis against Nutritional Blindness aims at universal synthetic vitamin A supplementation in all States without consideration of prevalence of deficiency, immunization status, under five mortality rate, dietary intake of vitamin A and access to health care. For example, despite widely varying child health and nutrition indicators, the States of Kerala and Uttar Pradesh have the same policy of vitamin A supplementation.

### Possible adverse effects {#sec3-4}

The potential adverse effects of administering a pharmacological dose of vitamin A to a child who is not suffering from deficiency, have not received due attention.

*Bulging fontanel*: Nearly12 per cent of young children when administered 50,000 IU of VA developed bulging fontanel[@ref30]. A significant proportion of brain development takes place before three years of age. In India, as per the National Family Health Survey (NFHS)-3[@ref31] 48 per cent of children suffer from undernutrition (below minus 2 SD). Subjecting these malnourished under three children to repeated episodes of increased intra-cranial tension could contribute to retarded brain development. There is lack of scientific evidence on the long term ill effects of these repeated episodes of raised intra-cranial tension on brain development of intrauterine growth retarded children who start their lives with psychomotor deficits[@ref32][@ref33].

*Vitamin D antagonism*: Animal studies suggest that vitamin A is an antagonist of vitamin D action. Massive doses of vitamin A intensify the severity of bone demineralization and inhibit the ability of vitamin D to prevent such demineralization. Increasing amounts of retinyl acetate produce progressive and significant decrease in total bone ash and increase in epiphyseal plate width. Increasing the levels of retinyl acetate abrogates the ability of vitamin D to elevate the level of serum calcium[@ref34][@ref35][@ref36][@ref37]. Considering, the current epidemic prevalence of vitamin D deficiency in the country, interventions potentially detrimental for bone health (massive dose VAS) are best avoided[@ref22].

*Potential zinc deficiency*: There is a possibility that zinc deficiency, which is already present in these children, could be aggravated by massive doses of vitamin A. Zinc is required for growth of children. Under these circumstances, the administration of massive doses of vitamin A to children who may be deficient in multiple vitamins including vitamin D and zinc could aggravate growth retardation. The potential role of massive-dose vitamin A prophylaxis in the persistence of stunting in poor children requires serious consideration[@ref22].

*Risk of acute respiratory infection*: Vitamin A administration has been associated with a significant increase in rate of pneumonia in well nourished children who received 10,000 IU of supplements weekly. A meta-analysis concluded that 'VAS has no consistent overall protective effect on the incidence of diarrhoea, however, it slightly increases the incidence of respiratory tract infections; hence, 'high dose vitamin A supplements are not recommended on a routine basis for all pre school children and should be offered only to individuals or populations with vitamin A deficiency'[@ref38].

A recent review of nine randomized controlled trials enrolling 33,179 children with lower respiratory tract infections (31,379 in the community and 1800 in hospital) concluded that vitamin A supplementation was not helpful for preventing pneumonia, at least in normally nourished children, and might rather worsen the situation. According to the investigators, the results should force the policy makers to think twice before continuing or starting a universal vitamin A supplementation programme[@ref39].

### Cost of vitamin A coverage {#sec3-5}

According to a recent evaluation, the annual cost per child dosed is 1.14 USD (![](IJMR-138-411-g002.jpg)=68) which includes: (i) programme-specific costs 0.42 USD (![](IJMR-138-411-g002.jpg)=26), (ii) personnel cost 0.55 USD (![](IJMR-138-411-g002.jpg)=33) and (iii) capital costs 0.17 USD (![](IJMR-138-411-g002.jpg)=6)[@ref40]. The total number of under five children in country will be about 160 million (15% of 1200 million). A cost of ![](IJMR-138-411-g002.jpg)= 8,000 million (160 million x ![](IJMR-138-411-g002.jpg)=50) is being spent and a large proportion of this expenditure is being undertaken for questionable health benefits of VAS to non deficient children. Apart from the cost of the micronutrient, the programme also consumes precious human and material resources meant for delivery of primary health care.

### Need for targeting VAS {#sec3-6}

WHO has recently issued guidelines[@ref41], which provide global, evidence-informed recommendations on the use of vitamin A supplements for the reduction of morbidity and mortality. According to these guidelines, vitamin A supplementation in children 6-59 months of age is recommended in settings where vitamin A deficiency is a public health problem. The mechanisms by which vitamin A reduces mortality are not fully understood, and it is not clear whether its action is mediated through the correction of underlying deficiencies or through adjuvant therapeutic effects[@ref41]. In the Indian context, it would, therefore, be prudent to restrict massive dose prophylaxis in isolated geographical pockets or areas where clinical vitamin A deficiency is a significant public health problem rather than continuing universal prophylaxis.

What approach should be adopted for VA supplementation? {#sec2-7}
-------------------------------------------------------

The era of gross and rampant vitamin A deficiency leading to blindness is past in India. At this stage, we should focus our efforts on sustainable food based approaches to combat vitamin A deficiency. The solution is to increase local production and consumption of green leafy vegetables and other plant foods that are rich sources of carotenoids. Green leafy vegetables, many fruits and other plant foods are also good sources of folate, vitamin C, Fe, Ca and many other micronutrients and bioactive compounds. These contribute to improvement of the overall nutritional status of children and protection against infectious and other diseases. The micronutrient deficiencies are often the result of lack of enough habitual food in the household rather than to the poor quality of such foods. When overall food intake becomes adequate enough to provide basic energy needs, needs of other nutrients would be met to a considerable extent even with the current diets. A food-based approach to combat VAD in non-clinically deficient areas would be a sustainable and cost effective solution[@ref42]. States of Bihar, Uttar Pradesh and Madhya Pradesh with poor intake of food providing all micronutrients, may have targeted approach of VAS in areas endemic for clinical VAD[@ref43].

In India, for cost-effective utilization of limited resources available to the health sector, the 'Triple A' (Assessment, Analysis and Action) strategy should be adopted; first, assess the problem of VAD, then undertake the detailed analysis of causes of VAD, and then decide the combination of approaches to be adopted for prevention and control in the community. Countries with limited financial resources and competing health priorities cannot afford the luxury of initiating interventions to raise serum biochemistry alone.

Conclusion {#sec1-2}
==========

In summary, India is currently at a stage when universal vitamin A supplementation must immediately transit to a targeted supplementation programme. The primary focus should be on adopting sustainable food based approaches to combat vitamin A deficiency.
